Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
194M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
351K
-
Shares change
-
+201K
-
Total reported value, excl. options
-
$14.3M
-
Value change
-
+$8.12M
-
Number of buys
-
3
-
Price
-
$40.37
Significant Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q4 2023
3 filings reported holding BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 351K shares
of 194M outstanding shares and own 0.18% of the company stock.
Largest 10 shareholders include Kohlberg Kravis Roberts & Co. L.P. (31.1M shares), VIKING GLOBAL INVESTORS LP (25.1M shares), VANGUARD GROUP INC (12.8M shares), BlackRock Inc. (10.2M shares), Aisling Capital Management LP (6.07M shares), Laurion Capital Management LP (5.24M shares), STATE STREET CORP (5.09M shares), Cormorant Asset Management, LP (3.34M shares), GOLDMAN SACHS GROUP INC (3.27M shares), and LORD, ABBETT & CO. LLC (3.1M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.